Support and Resources for Patients Taking Jakafi®


At IncyteCARES for Jakafi, our mission is to help eligible patients get started with their medicine and to provide information and support throughout their treatment.

Graphic of hand and checkmark
Coverage Verification

We can check with a patient’s insurance plan about their coverage for Jakafi and any out-of-pocket costs required.

Graphic of a hand and Rx
Insurance Information

We can help patients understand how their insurance plan works and provide information about prior authorization requirements. We can also offer information about appealing insurance denials or restrictions.

Graphic of a mailbox
Delivery Coordination

We can arrange to have the patient’s prescription for Jakafi filled by an approved specialty pharmacy and delivered directly to either the patient’s home or Healthcare Professional’s office.

Graphic of a copay assistance card
Copay/Coinsurance Assistance

For patients with commercial or private prescription drug coverage—eligible patients pay as little as $0 per month, subject to certain limits.*

Graphic of 2 patients
Patient Assistance Program (PAP)

Free product is offered to eligible patients who are uninsured or underinsured for Jakafi.

Graphic of a calendar
Temporary Coverage

For insurance coverage delays, eligible patients can receive a free short-term supply of Jakafi.

Graphic of a book
Patient Education and Support

Through our call center, IncyteCARES representatives can answer patient questions about their condition and Jakafi.

Graphic of a house
Connection to Other Support Services

For patients who need additional support beyond what we can provide directly, IncyteCARES can offer information about other independent organizations that may be able to help.

*Amount of savings for the purchase of Jakafi will not exceed $11,977 per month and $25,000 per year. Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE or any state medical or pharmaceutical assistance program. Valid prescription for Jakafi for an FDA-approved indication or compendia-recognized use is required. Please see complete Terms and Conditions or call IncyteCARES. Update effective as of January 1, 2021.

Terms, conditions, and additional eligibility criteria apply. Valid prescription for Jakafi for an FDA-approved indication or compendia-recognized use is required. Patients insured through Medicare Part D, Medicare Advantage, Medicaid, TRICARE, or a state medical assistance program are not eligible. Free product is offered to eligible patients without any purchase contingency or other obligation.


Once you’ve been prescribed Jakafi, you can either:
  • Call IncyteCARES to get started at 1-855-452-5234
  • OR

  • Ask your prescribing Healthcare Professional to enroll you

Note that not all patients who have been prescribed Jakafi are eligible to enroll in IncyteCARES or to receive all services we provide.

Visit to Learn More
Learn how IncyteCARES has helped support real patients

Hear from real patients who discuss their individual experiences with Jakafi and IncyteCARES.


Connect With
a Patient
Like Dan

Connect With a
Patient Like Dan

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Email Address

Continue Registering

Expand Collapse



Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.